NCT05621902 (LUCA-S) is a NA clinical trial of Weekly symptom monitoring in Lung Cancer, sponsored by Mats Lambe.

Who is sponsoring NCT05621902?

NCT05621902 is sponsored by Mats Lambe.

What drugs are being tested in NCT05621902?

Interventions in NCT05621902: Weekly symptom monitoring.

What condition does NCT05621902 study?

NCT05621902 studies Lung Cancer.

Is NCT05621902 still recruiting?

NCT05621902 is currently not yet recruiting. Last updated 18 November 2022.

Last reviewed 2022-11-18 · How we verify

NCT05621902: LUCA-S

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer

Not yet recruiting NA Last updated 18 November 2022

What this trial tests

NA trial testing Weekly symptom monitoring in Lung Cancer in 398 participants. Not yet recruiting.

Timeline

18 November 2022

Primary endpoint
30 June 2025

30 June 2027

Quick facts

Lead sponsor	Mats Lambe
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	398
Start date	18 November 2022
Primary completion	30 June 2025
Estimated completion	30 June 2027

Drugs / interventions tested

Weekly symptom monitoring

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Mats Lambe

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to investigate if weekly symptom monitoring of patients with advanced lung cancer is associated with better survival and improved quality of life compared to standard follow-up. Each week, participants in the intervention group will be asked to respond to an electronic weekly questionnaire covering 11 items related to current health status.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05621902 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mats Lambe
Last refreshed: 18 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05621902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing